CRMD — CorMedix Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 1410098 ·
Last close
$8.27
Market Cap
$648.80M
52W High
$8.94
52W Low
$6.13
ADV30
1,259,289
Next earnings
2026-08-06
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. CorMedix Inc. was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. The company was incorporated in 2006 and is based in Parsippany, New Jersey.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 127,427,000 105,122,000 63,658,000 38,601,000 815,637,000 178,087,000 378,588,000
Dec 2025 128,615,264 107,308,042 59,126,248 14,020,141 826,142,000 144,837,000 420,835,000
Sep 2025 104,275,289 93,080,673 51,345,966 108,562,980 750,861,478 48,493,076 376,732,072
Jun 2025 39,736,790 37,874,342 19,543,505 19,827,981 252,599,103 159,308,966 31,968,916

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$175,046,000
Investing CF
$-308,430,000
Financing CF
$238,453,000
CapEx
$-2,260,000
Dividends Paid
Buybacks
EPS Diluted TTM
$2.00
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-176,575,000
Inventory
$29,716,000
Receivables
$171,233,000
ST Investments
$3,694,000
EBIT TTM
$152,797,999
Pretax Income TTM
$150,016,000
Interest Exp TTM
$2,781,999
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$400,054,016
EBITDA
$228,804,992
Free Cash Flow
$119,837,056
Enterprise Value
$595,374,080
Total Cash
$178,087,008
Total Debt
$147,415,008
Shares Out
78,451,891
Trailing EPS
$2.17
Book Value
$5.58
ROE
65.6%
ROA
26.4%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 311,709,000 150,141,000 163,055,000 826,142,000 420,835,000 175,046,000
Dec 2024 43,472,000 -22,356,000 -17,930,000 118,846,000 34,189,000 -50,615,000
Dec 2023 0 -48,957,788 -46,339,227 82,059,957 11,917,528 -38,409,480
Dec 2022 65,408 -30,623,968 -29,701,705 62,038,259 6,978,523 -24,356,732

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.35

Peers — same industry

TickerNameMarket CapLastDaily %
MRVI MARAVAI LIFESCIENCES HOLDINGS, INC. $646.08M $4.38
CLYM Climb Bio, Inc. $652.20M $11.39
IRWD IRONWOOD PHARMACEUTICALS INC $641.99M $3.90
ANL Adlai Nortye Ltd. $666.64M $11.35
ACRS Aclaris Therapeutics, Inc. $629.88M $4.51

News headlines (Yahoo Finance, 1h cache)

CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms
2026-05-22 10:04 · Yahoo
Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)?
2026-05-17 19:08 · Yahoo
A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance
2026-05-16 12:11 · Yahoo
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
2026-05-15 14:11 · Yahoo
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
2026-05-15 12:30 · Yahoo
Cormedix Inc (CRMD) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
2026-05-14 23:02 · Yahoo
CorMedix Inc. Q1 2026 Earnings Call Summary
2026-05-14 20:45 · Yahoo
CorMedix (CRMD) Q1 2026 Earnings Transcript
2026-05-14 18:44 · Yahoo
CorMedix Q1 Earnings Call Highlights
2026-05-14 14:07 · Yahoo
CorMedix Shares Jump After Revenue Beat and Higher Full-Year Guidance
2026-05-14 14:06 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.